Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SPI-2012 in Breast Cancer Patients on TC Chemotherapy
NCT03135951Phase 1Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of esketamine in neutropenia, sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoints: Peak Plasma Concentration up to 42 days and Area Under the Curve up to 42 days. Started May 2017; status: completed.
02
Drugs
esketamine
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03135951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135951.